SWX:EVE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Evolva Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

24.3%

EVE

0.9%

CH Chemicals

1.5%

CH Market


1 Year Return

43.0%

EVE

21.7%

CH Chemicals

1.8%

CH Market

Return vs Industry: EVE exceeded the Swiss Chemicals industry which returned 20.2% over the past year.

Return vs Market: EVE exceeded the Swiss Market which returned 1.7% over the past year.


Shareholder returns

EVEIndustryMarket
7 Day24.3%0.9%1.5%
30 Day28.5%4.2%0.3%
90 Day49.1%15.8%7.9%
1 Year43.0%43.0%25.7%21.7%5.3%1.8%
3 Year-30.4%-41.6%49.0%34.9%22.2%9.5%
5 Year-78.1%-82.7%101.5%71.6%29.9%8.1%

Price Volatility Vs. Market

How volatile is Evolva Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evolva Holding undervalued compared to its fair value and its price relative to the market?

1.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVE is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: EVE is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVE is good value based on its PB Ratio (1.3x) compared to the CH Chemicals industry average (4.4x).


Next Steps

Future Growth

How is Evolva Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

29.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EVE's revenue (24% per year) is forecast to grow faster than the Swiss market (2.3% per year).

High Growth Revenue: EVE's revenue (24% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EVE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Evolva Holding performed over the past 5 years?

1.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVE is currently unprofitable.

Growing Profit Margin: EVE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVE is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare EVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVE is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (10.1%).


Return on Equity

High ROE: EVE has a negative Return on Equity (-12.54%), as it is currently unprofitable.


Next Steps

Financial Health

How is Evolva Holding's financial position?


Financial Position Analysis

Short Term Liabilities: EVE's short term assets (CHF48.7M) exceed its short term liabilities (CHF12.3M).

Long Term Liabilities: EVE's short term assets (CHF48.7M) exceed its long term liabilities (CHF7.2M).


Debt to Equity History and Analysis

Debt Level: EVE is debt free.

Reducing Debt: EVE has no debt compared to 5 years ago when its debt to equity ratio was 2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EVE has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 8.5% each year.


Next Steps

Dividend

What is Evolva Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVE's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Oliver Walker (51yo)

2yrs

Tenure

CHF914,200

Compensation

Mr. Oliver Walker has been Chief Executive Officer of Evolva Holding SA since July 10, 2018. Mr. Walker serves as Director of Kuros Biosciences AG since June 14, 2018. He served as the Chief Financial Offi ...


CEO Compensation Analysis

Compensation vs Market: Oliver's total compensation ($USD971.18K) is about average for companies of similar size in the Swiss market ($USD835.18K).

Compensation vs Earnings: Oliver's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Oliver Walker
Chief Executive Officer2yrsCHF914.20kno data
André Pennartz
Chief Financial Officer0.50yrno datano data
Scott Fabro
COO & Chief Commercial Officer2yrsno datano data
Barbara Duci
Head of Investor & Corporate Relationsno datano datano data
Nic Burgin
Head of Legal & Compliance and Secretary of the Boardno datano datano data
Simon Waddington
COO of Productsno datano datano data
Alessandro Del Fabro
Head of Finance3.5yrsno datano data
Astrid Schafer
Head of Research & Development2.5yrsno datano data
Clare Panchoo
Head of Health Ingredients0.83yrno datano data
Francesco Mennuti
Head of Supply Chain & Operations0.58yrno datano data

2.0yrs

Average Tenure

49yo

Average Age

Experienced Management: EVE's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Beat In-Albon
Chairman of the Board0.25yrno datano data
Richard Ridinger
Director0.25yrno datano data
Karl-Heinz Altmann
Member of Scientific Advisory Boardno datano datano data
Jay Keasling
Member of Scientific Advisory Boardno datano datano data
Vincent Martin
Member of Scientific Advisory Boardno datano datano data
Jörg Bohlmann
Member of Scientific Advisory Board4.92yrsno datano data
Birger Møller
Member of Scientific Advisory Boardno datano datano data
Karsten Kristiansen
Member of Scientific Advisory Boardno datano datano data
Stephan Schindler
Director0.25yrno datano data

0.3yrs

Average Tenure

65yo

Average Age

Experienced Board: EVE's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.


Top Shareholders

Company Information

Evolva Holding SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evolva Holding SA
  • Ticker: EVE
  • Exchange: SWX
  • Founded: 2004
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: CHF228.897m
  • Shares outstanding: 800.34m
  • Website: https://www.evolva.com

Number of Employees


Location

  • Evolva Holding SA
  • Duggingerstrasse 23
  • Reinach
  • Basel-Landschaft
  • 4153
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EVESWX (SIX Swiss Exchange)YesCommon SharesCHCHFSep 2009
ADFDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2009
ELVA.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2009
0QQJLSE (London Stock Exchange)YesCommon SharesGBCHFSep 2009
ELVA.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDFeb 2014

Biography

Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally. It offers branded ingredients, such as Veri-te Resveratrol, a natural ingredient in grapes, as well as other plants, including peanuts, cranberries, and Japanese knotweed for use in age-related health conditions; Nootkashield for pest control applications; EverSweet Stevia, a sweetener use in food, beverages, and table-top sweeteners; EveNootkatone, an ingredient for flavour and fragrance applications; and EveValencene, a citrus flavor. The company also develops and sells own products. It serves the nutrition, flavors and fragrances, animal health, personal care, and pharmaceutical markets. The company was founded in 2004 and is headquartered in Reinach, Switzerla. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 20:54
End of Day Share Price2020/07/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.